Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.10
HBIO's Cash to Debt is ranked higher than
66% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. HBIO: 1.10 )
HBIO' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 1.1

Equity to Asset 0.71
HBIO's Equity to Asset is ranked higher than
79% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. HBIO: 0.71 )
HBIO' s 10-Year Equity to Asset Range
Min: 0.68   Max: 0.93
Current: 0.71

0.68
0.93
Interest Coverage 1.61
HBIO's Interest Coverage is ranked lower than
52% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. HBIO: 1.61 )
HBIO' s 10-Year Interest Coverage Range
Min: 1.61   Max: 9999.99
Current: 1.61

1.61
9999.99
F-Score: 2
Z-Score: 2.57
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 1.46
HBIO's Operating margin (%) is ranked higher than
65% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. HBIO: 1.46 )
HBIO' s 10-Year Operating margin (%) Range
Min: -33.77   Max: 19.85
Current: 1.46

-33.77
19.85
Net-margin (%) -1.74
HBIO's Net-margin (%) is ranked higher than
63% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.08 vs. HBIO: -1.74 )
HBIO' s 10-Year Net-margin (%) Range
Min: -163.11   Max: 17.58
Current: -1.74

-163.11
17.58
ROE (%) -1.94
HBIO's ROE (%) is ranked higher than
63% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. HBIO: -1.94 )
HBIO' s 10-Year ROE (%) Range
Min: -368.49   Max: 21.07
Current: -1.94

-368.49
21.07
ROA (%) -1.35
HBIO's ROA (%) is ranked higher than
63% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. HBIO: -1.35 )
HBIO' s 10-Year ROA (%) Range
Min: -142.75   Max: 15.24
Current: -1.35

-142.75
15.24
ROC (Joel Greenblatt) (%) 5.44
HBIO's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.70 vs. HBIO: 5.44 )
HBIO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -159.92   Max: 36.65
Current: 5.44

-159.92
36.65
Revenue Growth (%) -3.60
HBIO's Revenue Growth (%) is ranked higher than
61% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. HBIO: -3.60 )
HBIO' s 10-Year Revenue Growth (%) Range
Min: -23.7   Max: 11.4
Current: -3.6

-23.7
11.4
EBITDA Growth (%) -28.80
HBIO's EBITDA Growth (%) is ranked higher than
51% of the 231 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. HBIO: -28.80 )
HBIO' s 10-Year EBITDA Growth (%) Range
Min: -28.8   Max: 29.1
Current: -28.8

-28.8
29.1
EPS Growth (%) -68.70
HBIO's EPS Growth (%) is ranked lower than
52% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.10 vs. HBIO: -68.70 )
HBIO' s 10-Year EPS Growth (%) Range
Min: -68.7   Max: 171.4
Current: -68.7

-68.7
171.4
» HBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

HBIO Guru Trades in Q3 2013

Arnold Van Den Berg 92,440 sh (New)
Jim Simons 420,171 sh (+13.87%)
John Hussman 1,000,000 sh (unchged)
Chuck Royce 767,100 sh (unchged)
» More
Q4 2013

HBIO Guru Trades in Q4 2013

Zeke Ashton 260,000 sh (New)
Arnold Van Den Berg 190,130 sh (+105.68%)
Jim Simons 489,200 sh (+16.43%)
Chuck Royce 767,100 sh (unchged)
John Hussman 930,000 sh (-7%)
» More
Q1 2014

HBIO Guru Trades in Q1 2014

Jim Simons 584,574 sh (+19.5%)
Zeke Ashton 285,000 sh (+9.62%)
John Hussman 930,000 sh (unchged)
Chuck Royce 767,100 sh (unchged)
Arnold Van Den Berg 190,130 sh (unchged)
» More
Q2 2014

HBIO Guru Trades in Q2 2014

Arnold Van Den Berg 190,130 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with HBIO

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Arnold Van Den Berg 2013-12-31 Add 105.68%0.04%$3.758 - $5.07 $ 4.8210%190130
Arnold Van Den Berg 2013-09-30 New Buy0.05%$3.6 - $4.28 $ 4.8223%92440
John Hussman 2011-12-31 Add 33.33%0.02%$2.92 - $3.75 $ 4.8247%1000000
John Hussman 2011-06-30 New Buy0.06%$3.72 - $4.65 $ 4.8217%750000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.60
HBIO's P/B is ranked higher than
88% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. HBIO: 1.60 )
HBIO' s 10-Year P/B Range
Min: 0.63   Max: 2.29
Current: 1.6

0.63
2.29
P/S 1.48
HBIO's P/S is ranked higher than
83% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. HBIO: 1.48 )
HBIO' s 10-Year P/S Range
Min: 0.51   Max: 2.66
Current: 1.48

0.51
2.66
PFCF 53.50
HBIO's PFCF is ranked higher than
78% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 83.00 vs. HBIO: 53.50 )
HBIO' s 10-Year PFCF Range
Min: 4.96   Max: 251.3
Current: 53.5

4.96
251.3
EV-to-EBIT 49.79
HBIO's EV-to-EBIT is ranked higher than
67% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.19 vs. HBIO: 49.79 )
HBIO' s 10-Year EV-to-EBIT Range
Min: 4.7   Max: 62.1
Current: 49.79

4.7
62.1
Shiller P/E 21.20
HBIO's Shiller P/E is ranked higher than
94% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. HBIO: 21.20 )
HBIO' s 10-Year Shiller P/E Range
Min: 8.95   Max: 34.97
Current: 21.2

8.95
34.97
Current Ratio 3.96
HBIO's Current Ratio is ranked higher than
84% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.79 vs. HBIO: 3.96 )
HBIO' s 10-Year Current Ratio Range
Min: 1.97   Max: 11.53
Current: 3.96

1.97
11.53
Quick Ratio 2.94
HBIO's Quick Ratio is ranked higher than
84% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. HBIO: 2.94 )
HBIO' s 10-Year Quick Ratio Range
Min: 1.15   Max: 10.71
Current: 2.94

1.15
10.71

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 18.50
HBIO's Price/Net Current Asset Value is ranked higher than
84% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. HBIO: 18.50 )
HBIO' s 10-Year Price/Net Current Asset Value Range
Min: 2.67   Max: 287.2
Current: 18.5

2.67
287.2
Price/Tangible Book 3.80
HBIO's Price/Tangible Book is ranked higher than
78% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.06 vs. HBIO: 3.80 )
HBIO' s 10-Year Price/Tangible Book Range
Min: 1.65   Max: 7.17
Current: 3.8

1.65
7.17
Price/DCF (Projected) 1.00
HBIO's Price/DCF (Projected) is ranked higher than
95% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.03 vs. HBIO: 1.00 )
HBIO' s 10-Year Price/DCF (Projected) Range
Min: 0.48   Max: 1.36
Current: 1

0.48
1.36
Price/Median PS Value 1.30
HBIO's Price/Median PS Value is ranked higher than
66% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. HBIO: 1.30 )
HBIO' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 4.16
Current: 1.3

0.62
4.16
Price/Graham Number 4.00
HBIO's Price/Graham Number is ranked higher than
75% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.73 vs. HBIO: 4.00 )
HBIO' s 10-Year Price/Graham Number Range
Min: 0.67   Max: 7.56
Current: 4

0.67
7.56
Earnings Yield (Greenblatt) 2.00
HBIO's Earnings Yield (Greenblatt) is ranked higher than
53% of the 252 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. HBIO: 2.00 )
HBIO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 21.2
Current: 2

1.6
21.2
Forward Rate of Return (Yacktman) -6.00
HBIO's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.95 vs. HBIO: -6.00 )
HBIO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.3   Max: 15.4
Current: -6

-5.3
15.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:HBI.Germany
Harvard Bioscience, Inc. is a Delaware corporation. The Company is a developer, manufacturer and marketer of a specialized products, mainly apparatus and scientific instruments, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories. It has sales and manufacturing operations in the United States, the United Kingdom, Germany and Spain and sales facilities in France and Canada. It sells its products to thousands of researchers in over 100 countries mainly through its 850 page catalog (and various other specialty catalogs), its website, through distributors, including GE Healthcare, Thermo Fisher Scientific Inc. and VWR, and via its field sales organization. Today, its broad product range is generally targeted towards two major application areas: ADMET testing and molecular biology and liquid handling. ADMET Testing - The ADMET testing identifies compounds that have toxic side effects or undesirable physiological or pharmacological properties. It has products that its customers use to help their researchers conduct better experiments on cells, tissues, organs and animals. The Company mainly sells these products under the Harvard Apparatus, BTX, KD Scientific, Hugo Sachs Elektronik, Panlab and Warner Instruments brand names. Molecular Biology and Liquid Handling - It mainly sells these products through its distributors, including GE Healthcare, under their brand names. These products are mainly scientific instruments such as spectrophotometers and plate readers that analyze light to detect and quantify molecular and cellular processes or apparatus such as gel electrophoresis units. The Company's end-user customers are mainly research scientists at pharmaceutical and biotechnology companies, universities and government laboratories, including the U.S. National Institutes of Health, or NIH. The Company's academic customers have included major colleges and universities such as Baylor College, Cambridge University, Harvard University, Johns Hopkins University, Massachusetts Institute of Technology, Yale University and the University of Texas - MD Anderson Center. The Company's pharmaceutical and biotechnological customers have included pharmaceutical companies and research laboratories such as Amgen, Inc., AstraZeneca plc, Genentech, Inc. and Johnson & Johnson. The Company is not subject to direct governmental regulation other than the laws and regulations generally applicable to businesses in the domestic and foreign jurisdictions in which it operates.
» More Articles for HBIO

Headlines

Articles On GuruFocus.com
Latest Stock Trades from Century Management: Buys POT, HWCC, PICO, AU, KGC Jan 15 2014 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Nov 05 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, Harvard Bioscience Inc, BGC Partners Inc., Chatham Lodg Sep 25 2010 
Weekly CEO Buys Highlight: Saul Centers Inc, Spartech Corp, Harvard Bioscience Inc, Rural/Metro Corp Sep 18 2010 
Harvard Bioscience Inc. Reports Operating Results (10-Q) May 07 2010 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Nov 09 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q) Aug 10 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q) May 07 2009 
Harvard Bioscience Inc. Reports Operating Results (10-Q/A) Feb 19 2009 
Harvard Bioscience, Inc. Schedules Fourth Quarter 2008 Conference Call for February 26, 2009 Feb 09 2009 

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide